Mouse anti-Human EPHA2 monoclonal antibody for WB, ELISA, IHC-P
WB: 1/500 - 1/2000; IHC-P: 5 μg/ml;
*Suggested working dilutions are given as a guide only. It is recommended that the user titrates the product for use in their own experiment using appropriate negative and positive controls.
EPHA2 (EPH Receptor A2) is a Protein Coding gene. Diseases associated with EPHA2 include cataract 6, multiple types and early-onset posterior subcapsular cataract. Among its related pathways are Stabilization and expansion of the E-cadherin adherens junction and EphB-EphrinB Signaling. GO annotations related to this gene include transferase activity, transferring phosphorus-containing groups and protein tyrosine kinase activity. An important paralog of this gene is EPHA3. This gene belongs to the ephrin receptor subfamily of the protein-tyrosine kinase family. EPH and EPH-related receptors have been implicated in mediating developmental events, particularly in the nervous system. Receptors in the EPH subfamily typically have a single kinase domain and an extracellular region containing a Cys-rich domain and 2 fibronectin type III repeats. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. Mutations in this gene are the cause of certain genetically-related cataract disorders.
Receptor for members of the ephrin-A family. Binds to ephrin-A1, -A3, -A4 and -A5. Plays an important role in angiogenesis and tumor neovascularization. The recruitement of VAV2, VAV3 and PI3-kinase p85 subunit by phosphorylated EPHA2 is critical for EFNA1-induced RAC1 GTPase activation and vascular endothelial cell migration and assembly (By similarity). Induces apoptosis in a p53/TP53-independent, caspase-8-dependent manner. Cataract 6, multiple types (CTRCT6) [MIM:116600]: An opacification of the crystalline lens of the eye that frequently results in visual impairment or blindness. Opacities vary in morphology, are often confined to a portion of the lens, and may be static or progressive. CTRCT6 includes posterior polar and age-related cortical cataracts, among others. Posterior polar cataract is a subcapsular opacity, usually disk-shaped, located at the back of the lens. Age-related cortical cataract is a developmental punctate opacity restricted to the cortex. The cataract is white or cerulean, increases in number with age, but rarely affects vision. Note=The disease is caused by mutations affecting the gene represented in this entry. Note=Overexpressed in several cancer types and promotes malignancy. EPH receptor A2 (ephrin type-A receptor 2) is a protein that in humans is encoded by the EPHA2 gene. The ephrin receptors are divided into 2 groups based on the similarity of their extracellular domain sequences and their affinities for binding ephrin-A and ephrin-B ligands. This gene encodes a protein that binds ephrin-A ligands. The function about EPHA2 antigen include ATP binding; ephrin receptor activity; nucleotide binding; protein binding; receptor activity; transmembrane receptor protein tyrosine kinase activity.
Arf6 signaling events, organism-specific biosystem; Axon guidance, organism-specific biosystem; Axon guidance, conserved biosystem; Direct p53 effectors, organism-specific biosystem; EPHA forward signaling, organism-specific biosystem; EPHA2 forward signaling, organism-specific biosystem; EphrinA-EPHA pathway, organism-specific biosystem.
Peng, L; Damschroder, MM; et al. Bi-Epitope SPR Surfaces: A Solution to Develop Robust Immunoassays. PLOS ONE 9:-(2014).
Jackson, D; Gooya, J; et al. A Human Antibody-Drug Conjugate Targeting EphA2 Inhibits Tumor Growth In vivo. CANCER RESEARCH 68:9367-9374(2008).
Custom Antibody Labeling
We offer labeled antibodies using our catalogue antibody products and a broad range of intensely fluorescent dyes and labels including HRP, biotin, ALP, Alexa Fluor® dyes, DyLight® Fluor dyes, R-phycoerythrin (R-PE), at scales from less than 100 μg up to 1 g of IgG antibody.